236 related articles for article (PubMed ID: 12095056)
21. Triple immunosuppression with or without basiliximab in pediatric renal transplantation: acute rejection rates at one year.
Duzova A; Buyan N; Bakkaloglu M; Dalgic A; Soylemezoglu O; Besbas N; Bakkaloglu A
Transplant Proc; 2003 Dec; 35(8):2878-80. PubMed ID: 14697926
[TBL] [Abstract][Full Text] [Related]
22. Anti-thymocyte globulin versus basiliximab induction in renal transplant recipients: Long-term outcome.
Kesiraju S; Paritala P; Rao Ch UM; Athmakuri SM; Reddy VS; Sahariah S
Saudi J Kidney Dis Transpl; 2014 Jan; 25(1):9-15. PubMed ID: 24434376
[TBL] [Abstract][Full Text] [Related]
23. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
[TBL] [Abstract][Full Text] [Related]
24. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal transplantation: a prospective, randomized study.
Kandus A; Arnol M; Omahen K; Oblak M; Vidan-Jeras B; Kmetec A; Bren AF
Transplantation; 2010 Apr; 89(8):1022-7. PubMed ID: 20075788
[TBL] [Abstract][Full Text] [Related]
25. Primary immunosuppression with mycophenolate mofetil and antithymocyte globulin for kidney transplant recipients of a suboptimal graft.
Grinyó JM; Gil-Vernet S; Seron D; Hueso M; Fulladosa X; Cruzado JM; Moreso F; Fernandez A; Torras J; Riera L; Castelao AM; Alsina J
Nephrol Dial Transplant; 1998 Oct; 13(10):2601-4. PubMed ID: 9794567
[TBL] [Abstract][Full Text] [Related]
26. A randomized, double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients.
Ponticelli C; Yussim A; Cambi V; Legendre C; Rizzo G; Salvadori M; Kahn D; Kashi H; Salmela K; Fricke L; Heemann U; Garcia-Martinez J; Lechler R; Prestele H; Girault D;
Transplantation; 2001 Oct; 72(7):1261-7. PubMed ID: 11602853
[TBL] [Abstract][Full Text] [Related]
27. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group.
Nashan B; Moore R; Amlot P; Schmidt AG; Abeywickrama K; Soulillou JP
Lancet; 1997 Oct; 350(9086):1193-8. PubMed ID: 9652559
[TBL] [Abstract][Full Text] [Related]
28. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.
Woodroffe R; Yao GL; Meads C; Bayliss S; Ready A; Raftery J; Taylor RS
Health Technol Assess; 2005 May; 9(21):1-179, iii-iv. PubMed ID: 15899149
[TBL] [Abstract][Full Text] [Related]
29. Results of kidney transplantation in patients receiving MMF- or MMF and basiliximab-containing immunosuppression.
Tojimbara T; Nakajima I; Sato S; Nakamura M; Kawase T; Kai K; Tsuda S; Kudo S; Fuchinoue S; Teraoka S
Transplant Proc; 2004 Sep; 36(7):2087-9. PubMed ID: 15518755
[TBL] [Abstract][Full Text] [Related]
30. Rabbit-ATG or basiliximab induction for rapid steroid withdrawal after renal transplantation (Harmony): an open-label, multicentre, randomised controlled trial.
Thomusch O; Wiesener M; Opgenoorth M; Pascher A; Woitas RP; Witzke O; Jaenigen B; Rentsch M; Wolters H; Rath T; Cingöz T; Benck U; Banas B; Hugo C
Lancet; 2016 Dec; 388(10063):3006-3016. PubMed ID: 27871759
[TBL] [Abstract][Full Text] [Related]
31. Induction Immunosuppressive Therapy Use in Deceased Donor Kidney Transplantation: 11-Year Experience in Veracruz, Mexico.
Martinez-Mier G; Soto-Miranda E; Avila-Pardo SF; Budar-Fernandez LF; Mateu-Rivera LJ; Mendez-Lopez MT; Trujillo-Martinez MF; Uscanga-Montesano A; Avila Y Falfan D
Transplant Proc; 2016 Mar; 48(2):600-4. PubMed ID: 27110011
[TBL] [Abstract][Full Text] [Related]
32. Rabbit antithymocyte globulin compared with basiliximab in kidney transplantation: a single-center study.
Kim JM; Jang HR; Kwon CH; Huh WS; Kim GS; Kim SJ; Joh JW; Oh HY
Transplant Proc; 2012 Jan; 44(1):167-70. PubMed ID: 22310606
[TBL] [Abstract][Full Text] [Related]
33. Use of basiliximab with mycophenolate mofetil in kidney transplantation.
Baron PW; Weissman J; Ojogho ON; Sahney S; Cutler D; James S; Oculam C; Abdelhalim F; Nehlsen-Cannarella SL; Teichman S; Concepcion W
Transplant Proc; 2003 Dec; 35(8):2881-4. PubMed ID: 14697927
[TBL] [Abstract][Full Text] [Related]
34. Two corticosteroid-free regimens-tacrolimus monotherapy after basiliximab administration and tacrolimus/mycophenolate mofetil-in comparison with a standard triple regimen in renal transplantation: results of the Atlas study.
Vítko S; Klinger M; Salmela K; Wlodarczyk Z; Tydèn G; Senatorski G; Ostrowski M; Fauchald P; Kokot F; Stefoni S; Perner F; Claesson K; Castagneto M; Heemann U; Carmellini M; Squifflet JP; Weber M; Segoloni G; Bäckman L; Sperschneider H; Krämer BK
Transplantation; 2005 Dec; 80(12):1734-41. PubMed ID: 16378069
[TBL] [Abstract][Full Text] [Related]
35. Randomized trial of tacrolimus plus mycophenolate mofetil or azathioprine versus cyclosporine oral solution (modified) plus mycophenolate mofetil after cadaveric kidney transplantation: results at 2 years.
Ahsan N; Johnson C; Gonwa T; Halloran P; Stegall M; Hardy M; Metzger R; Shield C; Rocher L; Scandling J; Sorensen J; Mulloy L; Light J; Corwin C; Danovitch G; Wachs M; VanVeldhuisen P; Salm K; Tolzman D; Fitzsimmons WE
Transplantation; 2001 Jul; 72(2):245-50. PubMed ID: 11477347
[TBL] [Abstract][Full Text] [Related]
36. Induction immunosuppressive therapy in renal transplantation: does basiliximab make the difference?
Jorge S; Guerra J; Silva S; Santana A; Mil-Homens C; Prata MM
Transplant Proc; 2008 Apr; 40(3):693-6. PubMed ID: 18454989
[TBL] [Abstract][Full Text] [Related]
37. Calcineurin inhibitor-free immunosuppression based on antithymocyte globulin and mycophenolate mofetil in cadaveric kidney transplantation: results after 5 years.
Grinyó JM; Gil-Vernet S; Cruzado JM; Caldés A; Riera L; Serón D; Rama I; Torras J
Transpl Int; 2003 Nov; 16(11):820-7. PubMed ID: 12879230
[TBL] [Abstract][Full Text] [Related]
38. Low-dose RATG with or without basiliximab in renal transplantation: a matched-cohort observational study.
Gentile G; Somma C; Gennarini A; Mastroluca D; Rota G; Lacanna F; Locatelli B; Remuzzi G; Ruggenenti P
Am J Nephrol; 2015; 41(1):16-27. PubMed ID: 25612603
[TBL] [Abstract][Full Text] [Related]
39. Reduced-exposure cyclosporine is safe and efficacious in de novo renal transplant recipients treated with enteric-coated mycophenolic acid and basiliximab.
Budde K; Bosmans JL; Sennesael J; Zeier M; Pisarski P; Schütz M; Fischer W; Neumayer HH; Glander P
Clin Nephrol; 2007 Mar; 67(3):164-75. PubMed ID: 17390741
[TBL] [Abstract][Full Text] [Related]
40. Use of basiliximab induction in low-immunological risk renal transplant recipients receiving tacrolimus-based immunosuppression.
Gavela Martínez E; Avila Bernabeu AI; Sancho Calabuig A; Beltrán Catalán S; Escudero Quesada V; Pallardó Mateu LM
Transplant Proc; 2009; 41(6):2337-8. PubMed ID: 19715913
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
